This information is current as of June 6, 2024.

Neuroimaging Findings in Patients with COVID-19

P. Nicholson, L. Alshafai and T. Krings

AJNR Am J Neuroradiol 2020, 41 (8) 1380-1383
doi: https://doi.org/10.3174/ajnr.A6630
http://www.ajnr.org/content/41/8/1380
Little has been published regarding neurologic outcomes in patients with coronavirus disease 2019 (COVID-19), and little is known about its neurologic sequelae. However, there is increasing interest regarding the prothrombotic nature of the disease. We wished to highlight our recent experience with 4 patients with COVID-19 with neurologic symptoms and suggest how their findings may point to the underlying pathophysiology involved.

**MATERIALS AND METHODS**

We reviewed clinical and imaging findings in a series of patients with COVID-19 who underwent neurologic imaging while admitted to our center. This imaging was initiated as a result of a change in clinical neurologic status, and the 4 patients were part of a larger cohort of patients with COVID-19 admitted.

**Patient 1**

A 43-year-old man was admitted for extracorporeal membrane oxygation (ECMO) following a failed trial of mechanical ventilation. On the fourth day, he developed acute pupil asymmetry. CT of the brain (Fig 1) showed a left frontal intraparenchymal hematoma with intraventricular hematoma and hydrocephalus. A fluid/fluid level was present within the hematoma, suggesting a possible underlying coagulopathy. There was a small amount of diffuse subarachnoid hemorrhage, petechial subcortical hemorrhage toward the vertex (arrow), and some hyperdense small cortical veins (arrowheads). No brain stem hemorrhage was present, but there was nearly complete effacement of the supratentorial CSF spaces. His white blood cell count was elevated at 15.2 $\times\ 10^9/L$, as was his D-dimer level ($4400\ mg/L$). His platelet count was in the normal range ($172\ /\ 10^9/L$), but his activated partial thromboplastin time was elevated (63.7 seconds) as was his prothrombin time (12.9 seconds) and serum ferritin level (2186 $\mu g/L$). He deteriorated and died shortly thereafter.

**Patient 2**

A 57-year-old man also underwent ECMO for respiratory failure. Following extubation, the patient demonstrated altered mental status and right-arm weakness. A CT scan (Fig 2) also showed multiple subcortical and subpial petechial hemorrhages. MR imaging, limited by motion artifacts (Fig 2 B–C), showed extensive petechial hemorrhages on SWI with some breakthrough small-volume parenchymal hematomas. There was also extensive parenchymal SWI abnormality, which appeared to correlate with a venular distribution and was predominantly in a subcortical pattern (as opposed, for example, to the deep gray matter SWI microhemorrhages, which can be seen in patients with hypertension). This subcortical SWI abnormality was not confined to 1 lobe of the brain but was rather more diffuse. The DWI sequences showed a few scattered multifocal cortical infarcts, but the
areas of abnormal subcortical SWI signal showed no DWI abnormality. There was no significant T2/FLAIR edema, and no mass effect or sulcal effacement in these regions. His white blood cell count was $16.3 \times 10^9/L$, and his D-dimer level exceeded $4400 \mu g/L$. His platelet count was also in the normal range ($174 \times 10^9/L$). His activated partial thromboplastin time was elevated at 63.7 seconds, as well as his prothrombin time (12.2 seconds) and his serum ferritin level ($4287 \mu g/L$).

Patient 3
A 62-year-old man was ventilated for 7 days without ECMO and was slow to awake. Findings of a CT scan were unremarkable; MR imaging (Fig 3) showed trace intraventricular blood (with dependent “layering” in the ventricle) on SWI. In addition, multifocal “blooming” was present in the subarachnoid and subpial spaces, tracking along the cortex in a gyriiform pattern. There was also extensive abnormal SWI signal tracking along small cortical veins in multiple territories and mild FLAIR hyperintensity along some cortical regions. High T2 signal was present in a subcortical distribution, along with callosal involvement. His white blood cell count was $14.3 \times 10^9/L$, his D-dimer level was $>4400 \mu g/L$, and his platelet count was in the normal range ($211 \times 10^9/L$). His activated partial thromboplastin time was 65.7 seconds, and his prothrombin time was 15.2 seconds. His C-reactive protein level was also markedly elevated at 285 mg/L.

Patient 4
A 57-year-old woman was placed on ECMO for 12 days for respiratory failure secondary to COVID-19. On the first day following cessation of ECMO, she developed bilateral mydriasis. Her white blood cell count was $13.2 \times 10^9/L$, D-dimer level was $<4400 \mu g/L$, and her platelet count was also in the normal range ($127 \times 10^9/L$). Activated partial thromboplastin time was 48.6 seconds, and prothrombin time, 11.6 seconds. Her C-reactive protein level was also elevated at 180 mg/L. A CT of the brain was performed (On-line Figure), which showed a large right-sided parenchymal temporal hemorrhage with midline shift. In addition, there were multiple other areas of petechial-type cortical and subcortical hemorrhages throughout both hemispheres. These appeared to be of mixed ages, and many had significant amounts of surrounding edema.

DISCUSSION
Little is known regarding effects of COVID-19 on the brain. Could it result in diffuse microvascular occlusion? Critical
illness–associated microbleeds are a recognized phenomenon, albeit with an unclear etiology. It is possible that they are related to a hyperthrombotic/hypercoagulable state. Severe sepsis is known to be associated with a range of downstream effects of the inflammatory cascade that result from the body’s attempts to fight infection, resulting in alterations in microvascular flow. In addition, a so-called “cytokine storm” has been implicated in COVID-19, and this phenomenon is known to have direct downstream effects on the vascular endothelium. The resultant thrombotic microangiopathy would then lead to end-organ dysfunction.

There is some evidence to support this hypothesis. Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) enters cells via the angiotensin-converting enzyme 2 receptor, which is widely expressed in both vascular smooth muscle and endothelium. Indeed 1 group has recently documented endothelial COVID-19 cell infection with endotheliitis and vasculitis in multiple organs. Others have shown a thromboembolism rate of 30% in severely ill patients with COVID-19, which is remarkably high considering that a multicenter study of >7400 critical care patients in 2015 showed thromboembolism rates of 7.7%. This elevated rate of thromboembolic complications has led some teams to speculate that it could also be due to an obstructive pulmonary microvascular thrombosis. Another group recently published skin and lung pathologic samples in patients with severe COVID-19 and skin rash. Their patients had extensive microvascular thrombosis.

Our imaging would be compatible with this theory, with multifocal abnormal SWI signal suggestive of a possible diffuse thrombotic microangiopathy, potentially with both arterial and venous components. Indeed, the multifocal cortical infarcts point toward a potential arterial microvascular thrombosis, while the hyperdense veins we saw on some studies could be indicative of sluggish venous flow. Unchecked diffuse thrombosis could then lead to blood-brain barrier breakdown, multifocal petechial bleeding, and eventual massive hemorrhage. Some patients could also then experience venous infarcts, which could explain the pattern seen in patient 1, for example.

This study has some caveats, of course. As stated earlier, cerebral microbleeds are a recognized phenomenon associated with critical care/sepsis (though the underlying mechanism may be similar to what we have stated). Some of the imaging findings we are seeing could be attributed to ECMO. For example, 1 series showed that up to 50% of patients having undergone ECMO experienced neurologic events, and other groups have shown similar imaging patterns. However, not all our patients were on ECMO despite similar imaging findings, so we believe it is more likely related to COVID-19 than to ECMO alone. Finally, we do not suggest that our limited single-center data are determinative, but rather hypothesis-generating.

CONCLUSIONS

We present a series of patients in keeping with the growing body of evidence regarding the prothrombic nature of patients with COVID-19. More data are needed regarding neuroimaging findings in these patients, but in the meantime, we strongly encourage clinicians to be aware of the possibility of a diffuse microvascular thrombotic-type picture and to have a low threshold for brain MR imaging in patients with COVID-19 with altered mental status.


REFERENCES


